Bone Therapeutics: Next 6 months should be decisiveBUY, Fair Value EUR26 (+31%)
We hosted Bone Therapeutics roadshow with E. Bastianelli (CEO) and W. Goemaere (CFO) yesterday in Paris. Since it raised EUR37m in the context of its Euronext listing in Feb. 2015, we were pleased to see the company delivering in time on its news flow. Looking into the end of the year and H1 2016, news flow should be even more dense. First efficacy data from the osteoporosis phase I/IIa trial expected within the next 6 months could be a game changer which might trigger a partnership.
For more information, please contact email@example.com